<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03314207</url>
  </required_header>
  <id_info>
    <org_study_id>AGTC-XLRP-001</org_study_id>
    <nct_id>NCT03314207</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of Patients With X-linked Retinitis Pigmentosa (XLRP)</brief_title>
  <official_title>Clinical Evaluation of Individuals With X-linked Retinitis Pigmentosa (XLRP) Caused by RPGR-ORF15 Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Applied Genetic Technologies Corp</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Applied Genetic Technologies Corp</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate subjects with X-linked retinitis pigmentosa caused&#xD;
      by RPGR-ORF15 mutations in a clinical setting to fully characterize their condition, measure&#xD;
      testing variability, and estimate rates of progression of clinical parameters.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Males with a clinical diagnosis of X-linked retinitis pigmentosa (XLRP) caused by RPGR-ORF15&#xD;
      mutations will be asked to provide informed consent and will have a single blood or saliva&#xD;
      sample obtained for DNA sequence analysis of genes known to cause XLRP, including the&#xD;
      RPGR-ORF15 gene. All participants will be informed of the results of testing for these&#xD;
      mutations. Those with qualifying mutations in the RPGR-ORF15 gene will be evaluated every 6&#xD;
      months for 3 years using a variety of non-invasive visual function tests to more fully&#xD;
      characterize their clinical condition. Testing will include routine ophthalmic examinations&#xD;
      and tests of visual acuity, perimetry, OCT, fundus imaging, and completion of quality of life&#xD;
      questionnaires.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Disease progression in subjects with XLRP</measure>
    <time_frame>Day 0 - Month 36</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease progression using visual acuity testing</measure>
    <time_frame>Day 0 - Month 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease progression using perimetry</measure>
    <time_frame>Day 0 - Month 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease progression using OCT</measure>
    <time_frame>Day 0 - Month 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease progression using electroretinography</measure>
    <time_frame>Day 0 - Month 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease progression using the National Eye Institute Visual Functioning Questionnaire-25 (VFQ-25) quality of life questionnaire</measure>
    <time_frame>Day 0 - Month 36</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">45</enrollment>
  <condition>X-Linked Retinitis Pigmentosa</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Males with a clinical diagnosis of X-linked Retinitis Pigmentosa (XLRP)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male subjects with a clinical diagnosis of XLRP and a documented molecular diagnosis&#xD;
             from a CLIA-certified laboratory of mutation within the ORF15 exon of the RPGR gene;&#xD;
&#xD;
          -  At least 6 years of age;&#xD;
&#xD;
          -  Willing and able to perform study procedures;&#xD;
&#xD;
          -  Signed informed consent(s) obtained (and child assent where applicable).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pre-existing eye conditions that would interfere with interpretation of study&#xD;
             endpoints (e.g. glaucoma, corneal or lenticular opacities, diabetic retinopathy,&#xD;
             history of retinal detachment);&#xD;
&#xD;
          -  Participating in an interventional research study of drugs or devices for treatment of&#xD;
             XLRP or other retinal diseases;&#xD;
&#xD;
          -  Monoocular participants&#xD;
&#xD;
          -  Any condition which leads the investigator to believe that the participant cannot&#xD;
             comply with the protocol requirements or that may place the participant at an&#xD;
             unacceptable risk for participation.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Feinsod, MD</last_name>
    <role>Study Director</role>
    <affiliation>Applied Genetics Technologies Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jill Dolgin, PharmD</last_name>
    <phone>833-770-2862</phone>
    <email>advocacy@agtc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Duke Eye Center, Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Casey Eye Institute, Oregon Health and Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Foundation of the Southwest</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 11, 2017</study_first_submitted>
  <study_first_submitted_qc>October 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2017</study_first_posted>
  <last_update_submitted>January 13, 2021</last_update_submitted>
  <last_update_submitted_qc>January 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>XLRP</keyword>
  <keyword>retinal degeneration</keyword>
  <keyword>RPGR</keyword>
  <keyword>ORF15</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

